London School of Economics and Political Science, Houghton Street, London, UK
Dr Panos Kanavos is Associate Professor in International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG).
Dr Kanavos has previously been Harkness Fellow in Health Care Policy in the Department of Ambulatory Care and Prevention, Harvard Medical School and has held visiting professor appointments at the University of Basel, the University of Delaware and the London School of Hygiene and Tropical Medicine. He is an economist by training, and teaches health economics, pharmaceutical economics and policy, health care financing, health care negotiations, and principles of health technology assessment.
He has acted as an advisor to a number of international governmental and non-governmental organizations, including the European Commission, the European Parliament, the World Bank, the World Health Organization, the Organization for Economic Co-operation and Development (OECD), the American Association for Retired Persons, and Ministries of Health of over 28 transition, emerging and developing countries.
Panos' research interests include comparative health policy and healthcare reform, pharmaceutical economics and policy from a developed and developing country perspective, quality and access in healthcare, and socio-economic determinants of health.
He leads the activities of MTRG, which is a research group comprising of 13 researchers and concentrates on interdisciplinary and comparative policy research on medical technologies. The group conducts research on a number of research streams. As part of its activities, MTRG is currently co-ordinating the activities of the IMPACT HTA consortium, an EU H2020 grant, and has previously coordinated the activities of key research grants on Health Technology Assessment (Advance HTA project), on Chronic Disease and a component of Best Practices in Rare Diseases . It has conducted research under the auspices of and participated in the European Medicines Information Network (EMI-net) and the network for the study of rare diseases . It also coordinates the activities of The Patient Academy, an initiative between academia, health care regulatory agencies and patient groups.
Expertise: health economics; health technology assessment; economics of medical technologies; pharmaceuticals; disease management; quality of care
LSE Consulting projects:
Access to medicines in Europe: Delays and challenges for timely patient access MSD, November 2021
The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health Sanofi, June 2021
Severe Asthma Healthcare Policy Audits AstraZeneca, May 2021
Predictive Analytic Tools and Value-based Health Care Takeda, February 2021
Access to Personalised Oncology in Europe European Federation of Pharmaceutical Industries and Associations (EFPIA), November 2020
Latin America Healthcare System Overview: A comparative analysis of fiscal space in healthcare F. Hoffmann-La Roche AG, August 2019
Pharmaceutical Policy in China Gilead Sciences, May 2019
Pharmaceutical Pricing and Reimbursement in the Middle East and North Africa Region: A Mapping of the Current Landscape and Options for the Future Pharmaceutical Research and Manufacturers of America (PhRMA), November 2018
Changing paradigms in the management of Multiple Sclerosis F. Hoffmann - La Roche, November 2018
Accelerated Approval and Access Schemes: A mapping of policies across the globe and the impact of accelerated approval on the HTA of new oncology medicines AstraZeneca, May 2017 – July 2018
European survey on the use of Real World Evidence F. Hoffmann - La Roche, January 2017 - May 2018
The use of Real World Evidence – Opportunities for Europe F. Hoffmann - La Roche, November 2016 - January 2018
External Reference Pricing within and across countries Pfizer, January 2016 - November 2017
Improving Outcomes for People with Multiple Sclerosis (MS): Review of the International MultiPlE Sclerosis Study (IMPrESS) findings F. Hoffmann - La Roche, October 2017
Understanding the Hepatocellular Carcinoma (HCC) Patient Landscape: Results of the first global survey of people living with HCC Sirtex Medical, January 2017 – November 2017
Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) Sogeti, August 2017
Controlling Pharmaceutical Expenditure and Improving Efficiency within the Spanish Pharmaceutical Market: Macro- and micro-level policy approaches Gilead Sciences, June 2017
Tender Loving Care? Purchasing Medicines for Continuing Therapeutic Improvement and Better Health Outcomes Baxalta (part of Shire), November 2016
Towards better outcomes in multiple sclerosis by addressing policy change: The International MultiPlE Sclerosis Study (IMPrESS) F. Hoffmann-La Roche, March 2016
The Value of Early Diagnosis and Treatment in Parkinson’s disease European Brain Council, March 2016
Cost and Impact of Non-Treating Severe Mental Illnesses (SMIs): The Case Study of Schizophrenia European Brain Council, January 2015
The Transatlantic Trade and Investment Partnership: International Trade Law, Health Systems, and Public Health European Public Health Alliance (EPHA), January 2015
Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries Novo Nordisk, January 2012
The Role of Funding and Policies on Innovation in Cancer Drug Development Novartis Pharma AG, September 2009
Pharmaceutical Reimbursement Policy in Turkey New Hope in Health Foundation (SUVAK), September 2005 The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis Johnson & Johnson, January 2004